Chinese regulators accept Zai Lab application for KarXT
Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...
Pharmaceutical Technology7h
FDA beats EMA to most approved new drugs in 2024
The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...
KOMU1d
FDA approves first new schizophrenia drug in more than 30 years
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
BioSpace4d
5 Novel FDA Approvals Notched in 2024
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
NBC 10 Philadelphia4d
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
Coventry must be 'more productive' in transfer window
Not too much should be read into 33-year-old Coventry-born forward Jamie Paterson training with The Sky Blues, with Lampard ...